Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab

• Published in: Scientific reports Vol. 13; no. 1; p. 2433
• Main Authors: Matsumoto, Toshihiko, Ikoma, Tatsuki, Yamamura, Shogo, Miura, Kou, Tsuduki, Takao, Watanabe, Takanori, Nagai, Hiroki, Takatani, Masahiro, Yasui, Hisateru
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 10-02-2023; Nature Publishing Group; Nature Portfolio
• Subjects: 631/67/1059; 631/67/1504; 631/67/322; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Bevacizumab; Bevacizumab - adverse effects; Colorectal cancer; Colorectal carcinoma; Colorectal Neoplasms - drug therapy; Colorectal Neoplasms - genetics; Disease control; Drug Combinations; Female; Humanities and Social Sciences; Humans; Hypertension; Male; Middle Aged; Monoclonal antibodies; multidisciplinary; Phenylurea Compounds - adverse effects; Pyrrolidines - therapeutic use; Retrospective Studies; Science; Science (multidisciplinary); Survival; Targeted cancer therapy; Thymine - therapeutic use; Trifluridine - therapeutic use; Uracil - therapeutic use
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-023-29706-6

Regorafenib is a standard salvage line therapy used for advanced colorectal cancer (CRC). Recently, trifluridine/tipiracil (TFTD) plus bevacizumab also showed promising efficacy as a salvage line therapy for advanced CRC. However, the efficacy and safety of regorafenib for patients with advanced CRC who have previously received TFTD plus bevacizumab is unclear. We retrospectively collected clinicopathologic data from patients with advanced CRC who received regorafenib after TFTD plus bevacizumab in multiple institutions between April 2017 and June 2020.Thirty-four advanced CRC patients who received regorafenib were analyzed. The median age was 66.5 (range 43–81 years), 11 patients were male, and all had an ECOG performance status(PS) of 0 or 1. Twenty-two patients had left-sided tumors, 18 patients had RAS mutants, and 1 patient had a BRAF V600E mutation. The response rate was 0%, and the disease control rate was 31%. The median progression-free survival was 70 days (95% CI: 56–91), and the overall survival was 233 days (95% CI: 188–324). Treatment was discontinued in 32 patients, and 28 (82%) discontinued treatment due to progressive disease. The major grade 3 and4 toxicities were proteinurea (29%), hypertension (26%), hand-foot syndrome(15%), and platelet decrease (6%). Regorafenib after TFTD plus bevacizumab showed efficacy similar to that of the previous study, and no new adverse events were observed.